TLDR:
- AITRICS, a medical AI company, raised ₩27.1 billion in Series B funding from Korean and foreign venture capital firms.
- They specialize in vital signals and developed AITRICS-VC, an AI solution for predicting patient deterioration.
Medical AI company AITRICS secured ₩27.1 billion in Series B funding from a combination of existing and new investors. The company, founded in 2016, focuses on vital signals and has developed AITRICS-VC, an AI solution for predicting patient deterioration. The software is capable of monitoring inpatients in real-time and predicting conditions such as sepsis, death, and cardiac arrest early on. With approval from the Ministry of Food and Drug Safety, the software is currently being used in over 40 hospitals in Korea. The new funds will be used to upgrade technology, develop new products, and obtain FDA approval in the U.S., paving the way for global expansion. AITRICS plans to continue strengthening their medical AI research and expanding their reach beyond Korea to benefit more doctors and patients worldwide.
